HIMS (Hims & Hers Health) — Comprehensive Analysis #
Date: 2026-03-15
Purpose: Evaluate squeeze/catalyst play thesis
Data Sources: yfinance, Finnhub
1. Price & Market Structure #
| Metric |
Value |
| Current Price |
$24.77 |
| Previous Close |
$23.84 |
| Day Range |
$23.25 – $24.82 |
| 52-Week High |
$70.43 (2025-07-31) |
| 52-Week Low |
$13.74 (2026-02-24) |
| 52-Week Return |
-21.5% |
| Market Cap |
$5.65B |
| Enterprise Value |
$6.19B |
| Beta |
2.61 |
| 200-day MA |
$42.17 |
| 50-day MA |
$24.20 |
2. Short Interest #
| Metric |
Value |
| Shares Short |
84.96M |
| Short % of Float |
46.09% |
| Short Ratio (Days to Cover) |
2.34 days |
| Float |
208.0M shares |
| Shares Outstanding |
219.6M |
3. Quarterly Financials #
| Quarter |
Revenue |
Gross Margin |
Op Income |
Net Income |
EPS |
EPS Beat |
| Q4 2024 |
$481.1M |
76.8% |
$18.6M |
$26.0M |
$0.23 |
+4% |
| Q1 2025 |
$586.0M |
73.5% |
$57.9M |
$49.5M |
$0.20 |
+65% |
| Q2 2025 |
$544.8M |
76.4% |
$26.7M |
$42.5M |
$0.17 |
+3% |
| Q3 2025 |
$599.0M |
73.8% |
$11.8M |
$15.8M |
$0.06 |
-41% |
| Q4 2025 |
$617.8M |
71.9% |
$9.2M |
$20.6M |
$0.08 |
+93% |
4. SBC-Adjusted Profitability #
| Quarter |
Net Income |
SBC |
SBC-Adj Net Income |
| Q1 2025 |
$49.5M |
$24.9M |
+$24.6M |
| Q2 2025 |
$42.5M |
$35.7M |
+$6.8M |
| Q3 2025 |
$15.8M |
$40.2M |
-$24.4M |
| Q4 2025 |
$20.6M |
$34.5M |
-$13.9M |
| FY2025 |
$128.4M |
$135.3M |
~-$6.9M |
5. Balance Sheet #
| Metric |
Q4 2025 |
Q4 2024 |
| Cash |
$228.6M |
$220.6M |
| Total Debt |
$1,120.6M |
$11.3M |
| Net Debt |
$744.0M |
n/a |
| Total Assets |
$2,154.7M |
$707.5M |
| Stockholders Equity |
$540.9M |
$476.7M |
6. Analyst Coverage #
| Metric |
Value |
| Opinions |
13 |
| Consensus |
Hold |
| Mean Target |
$23.11 |
| Median Target |
$23.00 |
| High Target |
$30.00 |
| Low Target |
$16.00 |
Current price $24.77 is already above the analyst consensus target.
7. Insider Activity Summary #
December 2025 (stock $35-37): Systematic selling by entire C-suite simultaneously — COO, CFO, multiple officers all sold.
January-February 2026 (stock declining): CFO continued exercise-and-sell.
Crash lows ($13-16): Only 1 minor sale ($70K), zero open-market purchases.
February-March 2026: RSU grants (compensation, not purchases).
No open-market purchases at any point during the 80% drawdown.
8. Squeeze Scorecard (shr-021) #
| Criterion |
Threshold |
HIMS |
Pass |
| Short % float >20% |
>20% |
46.1% |
YES |
| Days to cover >3 |
>3 |
2.34 |
NO |
| Float <100M |
<100M |
208M |
NO |
| Sustained buying pressure |
yes |
post-catalyst spike |
PARTIAL |
| Near-term catalyst |
yes |
Novo deal (already priced) |
PARTIAL |
| No dilution risk |
clean cap table |
$1.1B new debt, RSU grants |
AMBER |
Score: 1/6 hard criteria. Both hard filters (DTC and float) fail.
9. 3-Month Weekly Price #
| Week |
Close |
Volume |
Note |
| 2025-12-15 |
$35.56 |
58.6M |
|
| 2025-12-22 |
$34.31 |
37.3M |
C-suite selling |
| 2025-12-29 |
$33.41 |
47.9M |
|
| 2026-01-05 |
$31.69 |
81.2M |
|
| 2026-01-12 |
$31.38 |
84.3M |
|
| 2026-01-19 |
$29.62 |
72.8M |
|
| 2026-01-26 |
$27.09 |
88.4M |
|
| 2026-02-02 |
$23.02 |
184.3M |
GLP-1 fear begins |
| 2026-02-09 |
$16.30 |
287.6M |
Crash: -50% |
| 2026-02-16 |
$15.63 |
97.9M |
|
| 2026-02-23 |
$14.52 |
198.5M |
Near 52-wk low $13.74 |
| 2026-03-02 |
$15.74 |
120.9M |
Reddit entry price |
| 2026-03-09 |
$24.77 |
557.0M |
+57% Novo deal week |
10. Verdict #
Reddit Q4 revenue claim ($617.8M, +28%): CONFIRMED.
Novo Nordisk partnership: CONFIRMED, but the +57% move already happened.
$73.1 SqueezeFinder target: NOT CREDIBLE. Analyst high target is $30. Stock is at $24.77.
2.5M+ subscribers: PLAUSIBLE (prior reports showed ~2.2M as of Q3 2025).
The squeeze thesis fails the two hard mechanical filters (DTC 2.34, float 208M). The catalyst is already priced. The easy money ($13.74 to $24.77, +80%) has been made.